NCT00763750已完成2 期
BrUOG-Brain-223-A Phase II Study of PPX (CT-2103), Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors (CTI # CT2103) Principal Investigator: Howard Safran, M.D.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Number of Patients Assessed for Toxicity According to CTC Version 3.0
研究概览
简要总结
The purpose of this study is to determine the antitumor activity of PPX in combination with temozolomide and radiation for patients with newly diagnosed brain tumors.
详细描述
To evaluate the safety/tolerability and potential antitumor activity of PPX in combination with temozolomide and radiation for patients with newly diagnosed brain tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have histopathologically confirmed, newly diagnosed, glioblastoma multiforme or anaplastic glioma (anaplastic astrocytoma [AA], anaplastic oligodendroglioma, and anaplastic oligoastrocytoma) and have not had a complete surgical resection.
- •Patients must be 18 years of age or older.
- •Patients must have a Zubrod performance status 0-
- •Patients must not be on enzyme-inducing anti-epileptic drugs (EIAED). Patients may be on non-enzyme inducing anti-epileptic drugs (NEIAED) or may not be taking any anti-epileptic drugs.
- •Patients must not have received prior chemotherapy, radiation or any experimental therapy for their glioblastoma.
- •Patients may not be breast-feeding a child.
- •Female patients must either be not of child bearing potential or have a negative pregnancy test within 14 days of starting study treatment. Patients are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal. Pregnant or lactating females are not eligible. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- •Female patients must be using an acceptable method of contraception (oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, intrauterine device or tubal ligation) OR female patients must be at least 1-year post-menopausal or surgically sterile during their participation in this study (from the time they sign the consent form) to prevent pregnancy. Male patients must be surgically sterile or using an acceptable method of contraception during their participation in this study (from the time they sign the consent form) to prevent pregnancy in a partner
- •Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast. Patients with prior malignancies must be disease-free for ≥ 2 years.
- •Patients must have normal organ and marrow function as defined below:
- •Absolute neutrophil count > 1,500/ul
- •Platelets > 100,000/ul
- •Hemoglobin > 8 gm/dL
- •Total bilirubin < 1.5 x ULN
- •Creatinine < 1.5 x ULN
- •Patient must have the capacity to understand and the willingness to sign a written informed consent document.
- •Patient must be able to tolerate MRIs. CT scans can NOT be substituted for MRI in this study.
排除标准
- •Recurrent malignant gliomas.
- •Tumor foci detected below the tentorium or beyond the cranial vault.
- •Allergy to gadolinium or contraindication to MRI scan.
- •Patients who have received any form of brachytherapy or radiosurgery for their glioblastoma prior to start of standard radiation.
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to PPX.
- •Uncontrolled intercurrent illness including, but not limited to, hypertension ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Pregnant women are excluded from this study. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with PPX, breastfeeding should be discontinued if the mother is treated with PPX.
研究组 & 干预措施
PPX +TMZ+XRT
Experimental
XRT 60Gy at 2 GY/fractions x 30 fractions TMZ 75mg/m2/day PPX 40mg/m2/week x 6 weeks Days 1,8,15,22,22,29,36
干预措施: PPX +TMZ+XRT (Drug)
结局指标
主要结局
Number of Patients Assessed for Toxicity According to CTC Version 3.0
时间窗: Throughout the entire study until patient is removed from study an average of 6 weeks
次要结局
未报告次要终点
研究者
howard safran
Principle Investigator
Brown University
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/GlioblastomaGliomasGlioblastomaNCT00200161Memorial Sloan Kettering Cancer Center127
Unknown
2 期
Pemetrexed and Temozolomide in Treating Patients With Relapsed Primary Central Nervous System Lymphoma （PCNSL）Central Nervous System TumorsNCT01985451Rongjie Tao15
已完成
1 期
A Pilot Study of PPX in Women With Metastatic Colorectal CancerAdvanced Colorectal CancerNCT00598247University of Southern California15
Unknown
2 期
Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed GlioblastomaGlioblastomasGliosarcomaNCT00936052Neurological Surgery, P.C.20
撤回
2 期
Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell CancerRecurrent Head and Neck Squamous Cell CarcinomaUnresectable Head and Neck Squamous Cell CarcinomaNCT04834349M.D. Anderson Cancer Center